NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
Estimated value
£2.0bn
Awarded value
—
Suppliers
0
Lots
1
0 awarded
Published
17 Feb 2025
Deadline 07 Apr 2025
Description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Scope
- Reference
- CF-2825700D0O000000rwimUAA
- Total value
- £2,028,332,000 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2025 to 30 Aug 2027
- CPV classifications
- 33600000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 07 Apr 2025, 12:00 pm